cAMP-Elevating Agents for Neuropathy in Organic Acidemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for organic acidemia, including dietetic therapy, pharmacotherapy, dialysis, and transplantation, fail to completely prevent neuropathy, leading to severe neurological symptoms and a poor quality of life for patients, with no effective therapeutic drugs based on cAMP regulation available.
Innovation Solution
Development of a therapeutic drug that increases cAMP concentrations in nerve cells to treat and prevent neuropathy in organic acidemia by replenishing cAMP, using compounds such as Forskolin, GW9508, NECA, SKF77434, nicotinamide, dobutamine, and db-cAMP, which activate CREB and restore mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplantation is performed, then fatality rate decreases, but neuropathy is not completely cured and QOL deteriorates
Solution Approach 1:
The invention changes the biochemical parameter of cAMP concentration in nerve cells by administering cAMP-elevating agents. This parameter change directly addresses the neuropathy mechanism in organic acidemia without requiring additional transplantation procedures, thereby improving quality of life while maintaining the life-saving benefits of transplantation.
2Quantity of substance
If dietetic therapy is used, then organic acid accumulation is suppressed, but complete prevention of accumulation is not achieved
Solution Approach 1:
The invention introduces cAMP as an intermediary substance that mediates the protective effect against organic acid toxicity in nerve cells. By elevating cAMP levels, the body gains an additional defense mechanism that works alongside dietetic therapy to protect nerve cells, achieving more complete prevention than dietetic therapy alone.
3Speed
If pharmacotherapy with arginine, CARBAGLU, and carnitine hydrochloride is administered, then organic acids are rapidly eliminated, but complete exclusion of causative organic acids is not achieved
Solution Approach 1:
The invention changes the intracellular signaling parameter (cAMP concentration) in nerve cells to provide protection against organic acid toxicity. This complements the rapid elimination approach by adding a cellular defense mechanism that ensures complete protection even when some organic acids remain in the system.
Data Source
AI summary
[Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding.[Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.